Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR‐ANXA2, EGFR‐RAD51, ATR and BRCA2 mutations: A case report

Abstract

Here, we report a case of a 36‐year‐old female patient with metastatic non‐small cell lung cancer (NSCLC) harboring EGFR‐ANXA2 and EGFR‐RAD51 double fusion mutations with BRCA2 (nonsense mutation of exon 11) and ATR mutations (Exon 44 variable shear mutation) identified by next generation sequencing (NGS). The efficacy was significantly improved after lobaplatin combined with pemetrexed, temozolomide and bevacizumab. This is the first report of a novel mutation type EGFR‐ANXA2, as well as double EGFR fusion mutations in advanced lung adenocarcinoma. Furthermore, platinum‐based chemotherapy plus bevacizumab rather than targeted therapy showed favorable effects in this patient, providing a novel therapeutic conception for patients, even with multidriver mutations.

Keywords

• Bevacizumab
• chemotherapy
• EGFR fusion
• NGS
• NSCLC